Combined effects of clofibrate and diosgenin on cholesterol metabolism in rats.
Groups of male rats were fed various doses of clofibrate and diosgenin, both alone and in combination for 1 week. Clofibrate suppressed the diosgenin-induced increase in hepatic cholesterol synthesis but did not alter the effectiveness of diosgenin in reducing cholesterol absorption. Diosgenin did not affect the bioavailability of CPIB. Clofibrate reduced the diosgenin induced increase in biliary levels of cholesterol; none of the regimens altered biliary bile acids. The combination produced greater decreases in LDL cholesterol than did either compound alone; the diosgenin-induced elevation in HDL cholesterol was partially reversed by clofibrate. The data provide a basis for the combined use of clofibrate and diosgenin in the control of hyperlipoproteinemia.
D000042:Absorption; D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001682:Biological Availability; D002784:Cholesterol / Q000096:biosynthesis / Q000378:metabolism*; D002994:Clofibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006949:Hyperlipidemias / Q000188:drug therapy*; D008075:Lipoproteins, HDL / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D008297:Male; D051381:Rats; D013150:Spirostans / Q000008:administration & dosage / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D013150:Spirostans; D002784:Cholesterol; D002994:Clofibrate